Long-acting insulin up to phase 3 clinical end is expected to benefit children and adolescents with type 1 diabetes

Type 1 diabetes in children is an autoimmune disease characterized by the loss of immune-mediated islet beta cellsAccording to statistics, in the United States under the age of 18 people, one in 300 people with type 1 diabetesType 1 diabetes is insulin-dependent type diabetes, and its patients often cope with fluctuations in blood sugar levels, where too high blood sugar can cause ketosis, and ketoacidosis, while hypoglycemia can cause hypoglycemiaManaging blood sugar fluctuations is particularly challenging for children and adolescentsToujeo Gla-300, a long-acting insulin with three times the standard 1mL insulin content (100 units/mL), was approved by the FDA in 2015The main activity of insulin, including insulin glargine, is to regulate glucose metabolism by stimulating peripheral glucose intake, especially glucose intake of skeletal muscle and fat, and by inhibiting the production of glucose in the liver to reduce blood sugarEDITION JUNIOR Test Results (Photo Source: Resources 1)THE EDITION JUNIOR TRIAL, BETWEEN THE AGES OF 6 AND 17, GLYCATED HEMOGLOBIN LEVELS (HBA1C) IN PATIENTS WITH TYPE 1 DIABETES BETWEEN 7.5% AND 11.0 WERE TESTED TO REDUCE HBA1C LEVELS AND MANAGE BLOOD SUGAR FLUCTUATIONS (INCIDENCE OF KETONES AND HYPOGLYCEMIA) COMPARED TO TO TOU GLJEOA-100The Toujeo Gla-300 group achieved a major endpoint of reducing non-adverse effects on HbA1c levels, and the incidence of ketones and severe hypoglycemia (54 mg/dL) was relatively low"Globally, 50 to 80 percent of people with type 1 diabetes need more treatment options in order to meet the target of below 7.5 percent of HbA1c levels," said Dietmar Berger, head of global development at Sanofi,Sanofi hopes to provide children and adolescents with an additional treatment option to achieve personalized treatment and better control of the disease"
References:s1 s positive results in Phase 3 trial for Toujeo® in children and perse type 1 diabetesRetrieved Nov4, 2019, from http://, a summary of recent advances in the field of diabetes research (No 48) Retrieved Nov 4, 2019, from https://med.sina.com/article_detail_103_2_40398.html